UNH Stock Analysis: UnitedHealth | NYSE
Healthcare Plans | NYSE, USA | Market Cap: 392.028m USD | 12M Return: 47.3% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 2.38B
EPS Trend: -58.9%
Qual. Beats: 1
Rev. Trend: 99.6%
Qual. Beats: 1
Warnings
No concerns identified
Tailwinds
Seasonality 10.5 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
UnitedHealth Group is a diversified U.S. health care company organized into two main platforms: UnitedHealthcare, its insurance arm offering employer-sponsored, individual, Medicare, and Medicaid plans, and Optum, which provides health services, pharmacy benefits management, and technology/consulting to providers, payers, and other organizations. The business model combines risk-bearing insurance products with care delivery and pharmacy operations, creating vertical integration across the health care value chain.
The company serves a broad customer base spanning national and mid-sized employers, small businesses, public-sector programs (including Medicaid, CHIP, and Dual SNPs), and individual consumers. Founded in 1974 and headquartered in Eden Prairie, Minnesota, UNH operates in the Managed Health Care sub-industry and is listed on the NYSE.
- Optum Health and Optum Rx drive earnings growth and margin expansion
- Medicare Advantage star ratings and reimbursement rate updates impact UnitedHealthcare margins
- Change Healthcare cyberattack fallout pressures earnings and drives elevated remediation costs
| Net Income: 12.0b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.06 > 0.02 and ΔFCF/TA -1.74 > 1.0 |
| NWC/Revenue: -5.11% < 20% (prev -4.19%; Δ -0.92% < -1%) |
| CFO/TA 0.07 > 3% & CFO 23.2b > Net Income 12.0b |
| Net Debt (46.7b) to EBITDA (23.0b): 2.03 < 3 |
| Current Ratio: 0.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (910.0m) vs 12m ago -0.87% < -2% |
| Gross Margin: 18.80% > 18% (prev 21.99%; Δ -3.19% > 0.5%) |
| Asset Turnover: 144.5% > 50% (prev 132.4%; Δ 12.14% > 0%) |
| Interest Coverage Ratio: 4.71 > 6 (EBIT TTM 18.7b / Interest Expense TTM 3.96b) |
| A: -0.07 (Total Current Assets 91.1b - Total Current Liabilities 114b) / Total Assets 313b |
| B: 0.32 (Retained Earnings 99.9b / Total Assets 313b) |
| C: 0.06 (EBIT TTM 18.7b / Avg Total Assets 311b) |
| D: 0.50 (Book Value of Equity 104b / Total Liabilities 207b) |
| Altman-Z'' = 1.49 = BB |
| DSRI: 1.73 (Receivables 51.2b/26.9b, Revenue 450b/410b) |
| GMI: 1.17 (GM 21.99% / 18.80%) |
| AQI: 1.03 (AQ_t 0.67 / AQ_t-1 0.65) |
| SGI: 1.10 (Revenue 450b / 410b) |
| TATA: -0.04 (NI 12.0b - CFO 23.2b) / TA 313b) |
| Beneish M = -2.19 (Cap -4..+1) = BB |
As of July 16, 2026, the stock is trading at USD 418.52 with a total of 6,745,442 shares traded. Over the past week, the price has changed by -1.66%, over one month by +1.82%, over three months by +34.03% and over the past year by +47.31%.
Current recommended Stop Loss: 404.20 (which is 3.4% or 1.5 ATR below the current price).
UnitedHealth has received a consensus analysts rating of 4.15. Therefore, it is recommended to buy UNH.
- StrongBuy: 14
- Buy: 6
- Hold: 5
- Sell: 1
- StrongSell: 1
| Analysts Target Price | 420.5 | 0.5% |
P/E Trailing = 32.0475
P/E Forward = 23.31
P/S = 0.8717
P/B = 3.9487
P/EG = 1.4748
Revenue TTM = 450b USD
EBIT TTM = 18.7b USD
EBITDA TTM = 23.0b USD
Long Term Debt = 71.4b USD (from longTermDebt, last quarter)
Short Term Debt = 6.48b USD (from shortTermDebt, last quarter)
Debt = 77.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 46.7b USD (calculated: Debt 77.9b - CCE 31.2b)
Enterprise Value = 439b USD (392b + Debt 77.9b - CCE 31.2b)
Interest Coverage Ratio = 4.71 (Ebit TTM 18.7b / Interest Expense TTM 3.96b)
EV/FCF = 22.31x (Enterprise Value 439b / FCF TTM 19.7b)
FCF Yield = 4.48% (FCF TTM 19.7b / Enterprise Value 439b)
FCF Margin = 4.37% (FCF TTM 19.7b / Revenue TTM 450b)
Net Margin = 2.68% (Net Income TTM 12.0b / Revenue TTM 450b)
Gross Margin = 18.80% ((Revenue TTM 450b - Cost of Revenue TTM 365b) / Revenue TTM)
Gross Margin QoQ = 22.74% (prev 16.34%)
Tobins Q-Ratio = 1.40 (Enterprise Value 439b / Total Assets 313b)
Interest Expense / Debt = 5.08% (Interest Expense 3.96b / Debt 77.9b)
Taxrate = 11.96% (1.74b / 14.6b)
NOPAT = 16.4b (EBIT 18.7b * (1 - 11.96%))
Current Ratio = 0.80 (Total Current Assets 91.1b / Total Current Liabilities 114b)
Debt / Equity = 0.75 (Debt 77.9b / totalStockholderEquity, last quarter 104b)
Debt / EBITDA = 2.03 (Net Debt 46.7b / EBITDA 23.0b)
Debt / FCF = 2.37 (Net Debt 46.7b / FCF TTM 19.7b)
Total Stockholder Equity = 97.1b (last 4 quarters mean from totalStockholderEquity)
RoA = 3.87% (Net Income 12.0b / Total Assets 313b)
RoE = 12.40% (Net Income TTM 12.0b / Total Stockholder Equity 97.1b)
RoCE = 11.07% (EBIT 18.7b / Capital Employed (Equity 97.1b + L.T.Debt 71.4b))
RoIC = 9.00% (NOPAT 16.4b / Invested Capital 183b)
WACC = 5.66% (E(392b)/V(470b) * Re(5.89%) + D(77.9b)/V(470b) * Rd(5.08%) * (1-Tc(0.12)))
Discount Rate = 5.89% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -88.61 | Cagr: -1.20%
[DCF] Terminal Value 73.10% ; FCFF base≈21.7b ; Y1≈19.1b ; Y5≈15.4b
[DCF] Fair Price = 220.9 (EV 247b - Net Debt 46.7b = Equity 201b / Shares 908.1m; r=8.35% [WACC [floored]]; 5y FCF grow -15.0% → 2.50% )
EPS Correlation: -58.87 | EPS CAGR: -11.53% | SUE: 3.16 | # QB: 1
Revenue Correlation: 99.64 | Revenue CAGR: 9.69% | SUE: 1.97 | # QB: 1
EPS current Quarter (2026-06-30): EPS=4.85 | Chg30d=+0.03% | Revisions=-12% | Analysts=23
EPS next Quarter (2026-09-30): EPS=3.74 | Chg30d=+0.33% | Revisions=-12% | Analysts=22
EPS current Year (2026-12-31): EPS=18.42 | Chg30d=+0.18% | Revisions=+12% | GrowthEPS=+12.7% | GrowthRev=-0.8%
EPS next Year (2027-12-31): EPS=20.98 | Chg30d=+0.39% | Revisions=+73% | GrowthEPS=+13.9% | GrowthRev=+3.0%
[Analyst] Revisions Ratio: +27% (up=15, down=8)